Melanotan II 10mg

Melanotan II (MTII) is a potent appetite suppressor that rapidly reduces body mass. Given
the rapid loss of anorexic response upon chronic MTII treatment, most investigations have focused on
the initial physiological adaptations. However, other evidence supports MTII as a long-term modulator
of energy balance that remains to be established. Therefore, we examined the chronic effects of MTII on
energy homeostasis. MTII (high or low dose) or artificial cerebrospinal fluid (aCSF) was infused into the
lateral ventricle of the brain of 6-month-old F344BN rats (6–7/group) over 40 days. MTII suppressed
appetite in a dose-dependent manner (P < 0.05). Although food intake promptly rose back to control
level, body mass was persistently reduced in both MTII groups (P < 0.01). At day 40, both MTII groups
displayed lower adiposity than the aCSF animals (P < 0.01). These results show that MTII chronically
reduces body mass without the requirement of long-term caloric restriction. Our study proposes that
food restriction helps initiate mass loss; however, combined with a secondary pharmacological approach
preserving a negative energy balance state over time may help combat obesity. Melanotan II (MTII) is a
potent appetite suppressor that rapidly reduces body mass. Given the rapid loss of anorexic response
upon chronic MTII treatment, most investigations have focused on the initial physiological adaptations.
However, other evidence supports MTII as a long-term modulator of energy balance that remains to be
established. Therefore, we examined the chronic effects of MTII on energy homeostasis. MTII (high or
low dose) or artificial cerebrospinal fluid (aCSF) was infused into the lateral ventricle of the brain of 6-
month-old F344BN rats (6–7/group) over 40 days. MTII suppressed appetite in a dose-dependent
manner (P < 0.05). Although food intake promptly rose back to control level, body mass was persistently
reduced in both MTII groups (P < 0.01). At day 40, both MTII groups displayed lower adiposity than the
aCSF animals (P < 0.01). These results show that MTII chronically reduces body mass without the
requirement of long-term caloric restriction. Our study proposes that food restriction helps initiate mass
loss; however, combined with a secondary pharmacological approach preserving a negative energy
balance state over time may help combat obesity.
Reference:
Côté I, Sakarya Y, Kirichenko N, Morgan D, Carter CS, Tümer N, Scarpace PJ. Activation of the central
melanocortin system chronically reduces body mass without the necessity of long-term caloric
restriction. Can J Physiol Pharmacol. 2017 Feb;95(2):206-214. doi: 10.1139/cjpp-2016-0290. Epub 2016
Oct 19. PMID: 28051332; PMCID: PMC5572812.